サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1420995

インフルエンザ治療薬市場：世界の業界分析、規模、シェア、成長、動向、予測、2023～2031年

Influenza Medication Market (Product: Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine, Inosine, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

出版日
ページ情報
英文 159 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
インフルエンザ治療薬市場：世界の業界分析、規模、シェア、成長、動向、予測、2023～2031年
出版日: 2023年12月19日
発行: Transparency Market Research
ページ情報: 英文 159 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

インフルエンザ治療薬市場- レポートの範囲

世界のインフルエンザ治療薬市場に関するTMRのレポートは、過去と現在の成長動向、および2023年から2031年の予測期間中に市場の指標の貴重な洞察を得る機会を研究しています。このレポートは、世界のインフルエンザ治療薬市場の収益を提供し、2017年から2031年の期間、2023年を基準年、2031年を予測年とみなします。このレポートは、2023年から2031年までの世界のインフルエンザ治療薬市場の複合年間成長率（CAGR %）も提供します。

このレポートは広範な調査を経て作成されました。1次調査では、調査活動の大部分が行われ、アナリストが主要なオピニオンリーダー、業界リーダー、オピニオンメーカーにインタビューを実施しました。2次調査には、インフルエンザ治療薬市場を理解するために、主要企業の製品文献、年次報告書、プレスリリース、および関連文書の参照が含まれます。

市場スナップショット
2023年の市場価値 9億700万米ドル
2031年の市場価値 11億米ドル
CAGR 2.2%

このレポートは、世界のインフルエンザ治療薬市場の競合情勢を詳しく掘り下げています。世界のインフルエンザ治療薬市場で活動する主要企業が特定され、それぞれの企業がさまざまな属性の観点からプロファイルされています。会社概要、財務状況、最近の動向、 SWOTは、このレポートで紹介されている世界のインフルエンザ治療薬市場のプレーヤーの属性です。

目次

第1章 エグゼクティブサマリー

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • 市場セグメンテーション
  • 概要
  • 市場力学
  • 世界市場の分析と予測、2017～2031年

第5章 重要な洞察

  • パイプライン分析
  • COVID-19のパンデミックが業界に与える影響

第6章 市場分析と予測：製品タイプ別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：製品タイプ別、2017-2031
    • ザナミビル
    • オセルタミビル
    • ペラミビル
    • アマンタジン
    • リマンタジン
    • イノシン
    • その他（オクタン酸ラニナミビルなど）
  • 市場の魅力：製品タイプ別

第7章 世界市場の分析と予測：流通チャネル別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：流通チャネル別、2023-2031
    • 病院
    • クリニック
    • 薬局
    • その他
  • 市場の魅力：流通チャネル別

第8章 世界市場の分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別、2017-2031
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力：地域別

第9章 北米市場の分析と予測

第10章 欧州市場の分析と予測

第11章 アジア太平洋市場の分析と予測

第12章 ラテンアメリカ市場の分析と予測

第13章 中東およびアフリカ市場の分析と予測

第14章 競合情勢

  • 市場プレーヤー-競合マトリックス（企業の階層および規模別）
  • 市場シェア分析：企業別（2022年）
  • 企業プロファイル
    • F. Hoffmann-La Roche Ltd.,
    • Teva Pharmaceutical Industries Ltd.
    • Sandoz International GmbH
    • Sun Pharmaceutical Industries Ltd.
    • Mylan, Inc.
    • GlaxoSmithKline plc
    • Daiichi Sankyo Company
    • Natco Pharma
図表

List of Tables

  • Table 01: Global Influenza Medication Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 02: Global Influenza Medication Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 03: Global Influenza Medication Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 04: North America Influenza Medication Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 05: North America Influenza Medication Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 06: North America Influenza Medication Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 07: Europe Influenza Medication Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 08: Europe Influenza Medication Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 09: Europe Influenza Medication Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Asia Pacific Influenza Medication Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 11: Asia Pacific Influenza Medication Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 12: Asia Pacific Influenza Medication Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 13: Latin America Influenza Medication Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 14: Latin America Influenza Medication Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 15: Latin America Influenza Medication Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 16: Middle East & Africa Influenza Medication Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 17: Middle East & Africa Influenza Medication Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 18: Middle East & Africa Influenza Medication Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

List of Figures

  • Figure 01: Global Influenza Medication Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 02: Global Influenza Medication Market Value Share Analysis, by Product Type, 2022 and 2031
  • Figure 03: Global Influenza Medication Market Attractiveness Analysis, by Product Type, 2023-2031
  • Figure 04: Global Influenza Medication Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 05: Global Influenza Medication Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 06: Global Influenza Medication Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 07: Global Influenza Medication Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 08: North America Influenza Medication Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 09: North America Influenza Medication Market Value Share Analysis, by Product Type, 2022 and 2031
  • Figure 10: North America Influenza Medication Market Attractiveness Analysis, by Product Type, 2023-2031
  • Figure 11: North America Influenza Medication Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 12: North America Influenza Medication Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 13: North America Influenza Medication Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 14: North America Influenza Medication Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 15: Europe Influenza Medication Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 16: Europe Influenza Medication Market Value Share Analysis, by Product Type, 2022 and 2031
  • Figure 17: Europe Influenza Medication Market Attractiveness Analysis, by Product Type, 2023-2031
  • Figure 18: Europe Influenza Medication Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 19: Europe Influenza Medication Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 20: Europe Influenza Medication Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 21: Europe Influenza Medication Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 22: Asia Pacific Influenza Medication Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 23: Asia Pacific Influenza Medication Market Value Share Analysis, by Product Type, 2022 and 2031
  • Figure 24: Asia Pacific Influenza Medication Market Attractiveness Analysis, by Product Type, 2023-2031
  • Figure 25: Asia Pacific Influenza Medication Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 26: Asia Pacific Influenza Medication Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 27: Asia Pacific Influenza Medication Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 28: Asia Pacific Influenza Medication Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 29: Latin America Influenza Medication Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 30: Latin America Influenza Medication Market Value Share Analysis, by Product Type, 2022 and 2031
  • Figure 31: Latin America Influenza Medication Market Attractiveness Analysis, by Product Type, 2023-2031
  • Figure 32: Latin America Influenza Medication Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 33: Latin America Influenza Medication Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 34: Latin America Influenza Medication Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 35: Latin America Influenza Medication Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 36: Middle East & Africa Influenza Medication Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 37: Middle East & Africa Influenza Medication Market Value Share Analysis, by Product Type, 2022 and 2031
  • Figure 38: Middle East & Africa Influenza Medication Market Attractiveness Analysis, by Product Type, 2023-2031
  • Figure 39: Middle East & Africa Influenza Medication Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 40: Middle East & Africa Influenza Medication Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 41: Middle East & Africa Influenza Medication Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 42: Middle East & Africa Influenza Medication Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 43: Global Influenza Medication Market Share Analysis, by Company, 2022
目次
Product Code: TMRGL24038

Influenza Medication Market - Scope of Report

TMR's report on the global influenza medication market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global influenza medication market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global influenza medication market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the influenza medication market.

Market Snapshot
Market Value in 2023US$ 907 Mn
Market Value in 2031US$ 1.1 Bn
CAGR2.2%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global influenza medication market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global influenza medication market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global influenza medication market.

The report delves into the competitive landscape of the global influenza medication market. Key players operating in the global influenza medication market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global influenza medication market profiled in this report.

Key Questions Answered in Global influenza medication Market Report:

  • What is the sales/revenue generated by influenza medication across all regions during the forecast period?
  • What are the opportunities in the global influenza medication market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Influenza Medication Market - Research Objectives and Research Approach

The comprehensive report on the global influenza medication market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global influenza medication market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global influenza medication market.

Table of Contents

1. Executive Summary

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Influenza Medication Market

4. Market Overview

  • 4.1. Market Segmentation
    • 4.1.1. Segment Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Influenza Medication Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. COVID-19 Pandemic Impact on Industry

6. Influenza Medication Market Analysis and Forecast, by Product Type

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Product Type, 2017-2031
    • 6.3.1. Zanamivir
    • 6.3.2. Oseltamivir
    • 6.3.3. Peramivir
    • 6.3.4. Amantadine
    • 6.3.5. Rimantadine
    • 6.3.6. Inosine
    • 6.3.7. Others (Laninamivir Octanoate, etc.)
  • 6.4. Market Attractiveness, by Product Type

7. Global Influenza Medication Market Analysis and Forecast, by Distribution Channel

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Distribution Channel, 2023-2031
    • 7.3.1. Hospitals
    • 7.3.2. Clinics
    • 7.3.3. Pharmacies
    • 7.3.4. Others
  • 7.4. Market Attractiveness, by Distribution Channel

8. Global Influenza Medication Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region, 2017-2031
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness, by Region

9. North America Influenza Medication Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. Market Value Forecast, by Product Type, 2017-2031
    • 9.2.1. Zanamivir
    • 9.2.2. Oseltamivir
    • 9.2.3. Peramivir
    • 9.2.4. Amantadine
    • 9.2.5. Rimantadine
    • 9.2.6. Inosine
    • 9.2.7. Others (Laninamivir Octanoate, etc.)
  • 9.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 9.3.1. Hospitals
    • 9.3.2. Clinics
    • 9.3.3. Pharmacies
    • 9.3.4. Others
  • 9.4. Market Value Forecast, by Country, 2017-2031
    • 9.4.1. U.S.
    • 9.4.2. Canada
  • 9.5. Market Attractiveness Analysis
    • 9.5.1. By Product Type
    • 9.5.2. By Distribution Channel
    • 9.5.3. By Country

10. Europe Influenza Medication Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Product Type, 2017-2031
    • 10.2.1. Zanamivir
    • 10.2.2. Oseltamivir
    • 10.2.3. Peramivir
    • 10.2.4. Amantadine
    • 10.2.5. Rimantadine
    • 10.2.6. Inosine
    • 10.2.7. Others (Laninamivir Octanoate, etc.)
  • 10.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.3.1. Hospitals
    • 10.3.2. Clinics
    • 10.3.3. Pharmacies
    • 10.3.4. Others
  • 10.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 10.4.1. Germany
    • 10.4.2. U.K.
    • 10.4.3. France
    • 10.4.4. Italy
    • 10.4.5. Spain
    • 10.4.6. Rest of Europe
  • 10.5. Market Attractiveness Analysis
    • 10.5.1. By Product Type
    • 10.5.2. By Distribution Channel
    • 10.5.3. By Country/Sub-region

11. Asia Pacific Influenza Medication Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Product Type, 2017-2031
    • 11.2.1. Zanamivir
    • 11.2.2. Oseltamivir
    • 11.2.3. Peramivir
    • 11.2.4. Amantadine
    • 11.2.5. Rimantadine
    • 11.2.6. Inosine
    • 11.2.7. Others (Laninamivir Octanoate, etc.)
  • 11.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.3.1. Hospitals
    • 11.3.2. Clinics
    • 11.3.3. Pharmacies
    • 11.3.4. Others
  • 11.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.4.1. China
    • 11.4.2. Japan
    • 11.4.3. India
    • 11.4.4. Australia & New Zealand
    • 11.4.5. Rest of Asia Pacific
  • 11.5. Market Attractiveness Analysis
    • 11.5.1. By Product Type
    • 11.5.2. By Distribution Channel
    • 11.5.3. By Country/Sub-region

12. Latin America Influenza Medication Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Product Type, 2017-2031
    • 12.2.1. Zanamivir
    • 12.2.2. Oseltamivir
    • 12.2.3. Peramivir
    • 12.2.4. Amantadine
    • 12.2.5. Rimantadine
    • 12.2.6. Inosine
    • 12.2.7. Others (Laninamivir Octanoate, etc.)
  • 12.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.3.1. Hospitals
    • 12.3.2. Clinics
    • 12.3.3. Pharmacies
    • 12.3.4. Others
  • 12.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.4.1. Brazil
    • 12.4.2. Mexico
    • 12.4.3. Rest of Latin America
  • 12.5. Market Attractiveness Analysis
    • 12.5.1. By Product Type
    • 12.5.2. By Distribution Channel
    • 12.5.3. By Country/Sub-region

13. Middle East & Africa Influenza Medication Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Product Type, 2017-2031
    • 13.2.1. Zanamivir
    • 13.2.2. Oseltamivir
    • 13.2.3. Peramivir
    • 13.2.4. Amantadine
    • 13.2.5. Rimantadine
    • 13.2.6. Inosine
    • 13.2.7. Others (Laninamivir Octanoate, etc.)
  • 13.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.3.1. Hospitals
    • 13.3.2. Clinics
    • 13.3.3. Pharmacies
    • 13.3.4. Others
  • 13.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.4.1. GCC Countries
    • 13.4.2. South Africa
    • 13.4.3. Rest of Middle East & Africa
  • 13.5. Market Attractiveness Analysis
    • 13.5.1. By Product Type
    • 13.5.2. By Distribution Channel
    • 13.5.3. By Country/Sub-region

14. Competition Landscape

  • 14.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 14.2. Market Share Analysis, by Company (2022)
  • 14.3. Company Profiles
    • 14.3.1. F. Hoffmann-La Roche Ltd.,
      • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.1.2. Product Portfolio
      • 14.3.1.3. Financial Overview
      • 14.3.1.4. SWOT Analysis
      • 14.3.1.5. Strategic Overview
    • 14.3.2. Teva Pharmaceutical Industries Ltd.
      • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.2.2. Product Portfolio
      • 14.3.2.3. Financial Overview
      • 14.3.2.4. SWOT Analysis
      • 14.3.2.5. Strategic Overview
    • 14.3.3. Sandoz International GmbH
      • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.3.2. Product Portfolio
      • 14.3.3.3. Financial Overview
      • 14.3.3.4. SWOT Analysis
      • 14.3.3.5. Strategic Overview
    • 14.3.4. Sun Pharmaceutical Industries Ltd.
      • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.4.2. Product Portfolio
      • 14.3.4.3. Financial Overview
      • 14.3.4.4. SWOT Analysis
      • 14.3.4.5. Strategic Overview
    • 14.3.5. Mylan, Inc.
      • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.5.2. Product Portfolio
      • 14.3.5.3. Financial Overview
      • 14.3.5.4. SWOT Analysis
      • 14.3.5.5. Strategic Overview
    • 14.3.6. GlaxoSmithKline plc
      • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.6.2. Product Portfolio
      • 14.3.6.3. Financial Overview
      • 14.3.6.4. SWOT Analysis
      • 14.3.6.5. Strategic Overview
    • 14.3.7. Daiichi Sankyo Company
      • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.7.2. Product Portfolio
      • 14.3.7.3. Financial Overview
      • 14.3.7.4. SWOT Analysis
      • 14.3.7.5. Strategic Overview
    • 14.3.8. Natco Pharma
      • 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.8.2. Product Portfolio
      • 14.3.8.3. Financial Overview
      • 14.3.8.4. SWOT Analysis
      • 14.3.8.5. Strategic Overview